Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Prizes
Activities
Press/Media
Student theses
Search by expertise, name or affiliation
View Scopus Profile
Ori Tal
Doctor
Lecturer
,
Faculty of Medicine
,
Obstetrics & Gynecology
2019
2024
Research activity per year
Overview
Fingerprint
Network
Research output
(15)
Similar Profiles
(7)
Fingerprint
Dive into the research topics where Ori Tal is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Medical Treatment
95%
Endometrial Cancer
95%
Epithelial Ovarian Cancer
66%
Adverse Pregnancy Outcomes
63%
Early Pregnancy Loss
63%
Surgical Intervention
61%
Retrospective Cohort Study
57%
Ultrasound
53%
Curettage
47%
Israeli
39%
Treatment Outcome
39%
Ovarian Cancer Patients
39%
Adverse Neonatal Outcome
37%
Cancer Patients
37%
Treatment Failure
36%
Overall Survival
35%
Prognostic Factors
34%
In Vitro Fertilization
31%
Vaginal Examination
31%
End-of-life Symptom Management
31%
Meconium Staining
31%
Lymph Node Recurrence
31%
Meconium-stained Amniotic Fluid
31%
Retroperitoneal Lymph Node
31%
Perineal Trauma
31%
Cancer Prognostics
31%
Coagulation Testing
31%
Postmenopausal Patients
31%
Low-grade Serous Ovarian Cancer
31%
Intraperitoneal Local Anaesthetic
31%
Intraperitoneal Analgesia
31%
Spontaneous Preterm Birth (sPTB)
31%
Amniotic Fluid
31%
Borderline Ovarian Tumor
31%
Preeclampsia
31%
Sentinel Lymph Node Mapping
31%
Thrombocytosis
31%
Age Disparity
31%
Prognostic Significance
31%
Gynecologic Oncology Group
31%
Group Studies
31%
Placebo
31%
Placental Pathology
31%
Abnormal Coagulation
31%
Anatomic
31%
Randomized Controlled Trial
31%
Trocar Site
31%
Rare Diseases
31%
Body Mass Index
31%
Gestational Age
31%
Medicine and Dentistry
Krukenberg Tumor
100%
Combination Therapy
95%
Endometrial Cancer
95%
Recurrent Disease
71%
Prognostic Factor
68%
Disease
68%
Surgery
67%
Ovarian Cancer
63%
First Trimester Pregnancy
63%
Retrospective Cohort Study
57%
CA-125
42%
Ovarian Tumor
36%
Dilation and Curettage
36%
Gynecological Oncology
31%
Rare Disease
31%
Parthenogenesis
31%
Gestational Age
31%
Debulking
31%
In Vitro Fertilisation
31%
Analgesia
31%
Sentinel Lymph Node
31%
Perineum Injury
31%
Symptom
31%
Spontaneous Abortion
31%
Coagulation Testing
31%
Meconium
31%
Randomized Controlled Trial
31%
Thrombocytosis
31%
Menstrual Cycle
31%
Amnion Fluid
31%
Symptom Management
31%
Paraaortic Lymph Node
31%
Histopathology
31%
Pre-Eclampsia
31%
Body Mass Index
31%
Laparoscopy
29%
Placebo
26%
Symptomatic Treatment
23%
Overall Survival
23%
Crown-Rump Length
21%
Platelet
21%
Bupivacaine
21%
Hysteroscopy
20%
Indocyanine Green
19%
Pelvis
16%
Technetium
15%
Sulfur
15%
Sodium Chloride
15%
Postoperative Pain
15%
Disease Specific Survival
15%
